{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:39:31Z","timestamp":1792449571729,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","award":["19-09086S"],"award-info":[{"award-number":["19-09086S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007059","name":"Univerzita Palack\u00e9ho v Olomouci","doi-asserted-by":"publisher","award":["IGA PrF 2021 007"],"award-info":[{"award-number":["IGA PrF 2021 007"]}],"id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.bmcl.2022.128603","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T11:59:55Z","timestamp":1643889595000},"page":"128603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Synthesis and biological activity evaluation of novel 2,6,9-trisubstituted purine conjugates as potential protein kinases inhibitors"],"prefix":"10.1016","volume":"60","author":[{"given":"Krist\u00fdna","family":"Vlkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Guck\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Pe\u0159ina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4773-2850","authenticated-orcid":false,"given":"Eva","family":"\u0158ezn\u00ed\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Kry\u0161tof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bmcl.2022.128603_b0005","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cytogfr.2004.03.007","article-title":"The PDGF family: four gene products form five dimeric isoforms","volume":"15","author":"Fredriksson","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bmcl.2022.128603_b0010","doi-asserted-by":"crossref","unstructured":"Heldin C-H, Lennartsson J. Structural and Functional Properties of Platelet-Derived Growth Factor and Stem Cell Factor Receptors. Cold Spring Harb Perspect Biol. 2013;5(8):a009100-a009100. 10.1101\/cshperspect.a009100.","DOI":"10.1101\/cshperspect.a009100"},{"issue":"8","key":"10.1016\/j.bmcl.2022.128603_b0015","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2013.05.002","article-title":"Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis","volume":"19","author":"Cao","year":"2013","journal-title":"Trends Mol Med."},{"issue":"9","key":"10.1016\/j.bmcl.2022.128603_b0020","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2217\/fon.14.83","article-title":"PDGF receptors in tumor biology: prognostic and predictive potential","volume":"10","author":"Paulsson","year":"2014","journal-title":"Futur Oncol."},{"issue":"2","key":"10.1016\/j.bmcl.2022.128603_b0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11481-013-9484-2","article-title":"Targeting the PDGF Signaling Pathway in the Treatment of Non-Malignant Diseases","volume":"9","author":"Heldin","year":"2014","journal-title":"J Neuroimmune Pharmacol."},{"issue":"5","key":"10.1016\/j.bmcl.2022.128603_b0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/pin.12530","article-title":"Pathogenetic significance and possibility as a therapeutic target of platelet derived growth factor","volume":"67","author":"Ishii","year":"2017","journal-title":"Pathol Int."},{"issue":"11","key":"10.1016\/j.bmcl.2022.128603_b0035","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.tibs.2005.09.005","article-title":"Mammalian cyclin-dependent kinases","volume":"30","author":"Malumbres","year":"2005","journal-title":"Trends Biochem Sci."},{"issue":"5","key":"10.1016\/j.bmcl.2022.128603_b0040","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"issue":"3-4","key":"10.1016\/j.bmcl.2022.128603_b0045","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000134046","article-title":"Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12→q13","volume":"70","author":"Carow","year":"1995","journal-title":"Cytogenet Genome Res."},{"issue":"7","key":"10.1016\/j.bmcl.2022.128603_b0050","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/13543776.2010.493559","article-title":"Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature","volume":"20","author":"Dai","year":"2010","journal-title":"Expert Opin Ther Pat."},{"key":"10.1016\/j.bmcl.2022.128603_b0055","doi-asserted-by":"crossref","unstructured":"Stirewalt DL, Kopecky KJ, Meshinchi S, et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood. 2006;107(9):3724-3726. 10.1182\/blood-2005-08-3453.","DOI":"10.1182\/blood-2005-08-3453"},{"issue":"10","key":"10.1016\/j.bmcl.2022.128603_b0060","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/sj.leu.2400812","article-title":"Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines","volume":"11","author":"Yokota","year":"1997","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.bmcl.2022.128603_b0065","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1002\/cncr.25908","article-title":"FLT3 inhibitors in the treatment of acute myeloid leukemia","volume":"117","author":"Pemmaraju","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bmcl.2022.128603_b0070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2040620714532123","article-title":"The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond","volume":"5","author":"Wander","year":"2014","journal-title":"Ther Adv Hematol."},{"key":"10.1016\/j.bmcl.2022.128603_b0075","doi-asserted-by":"crossref","unstructured":"Zimmerman EI, Turner DC, Buaboonnam J, et al. Crenolanib is active against models of drug-resistant FLT3-ITD\u2212positive acute myeloid leukemia. Blood. 2013;122(22):3607-3615. 10.1182\/blood-2013-07-513044.","DOI":"10.1182\/blood-2013-07-513044"},{"key":"10.1016\/j.bmcl.2022.128603_b0080","doi-asserted-by":"crossref","unstructured":"Lee LY, Hernandez D, Rajkhowa T, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood. 2017;129(2):257-260. 10.1182\/blood-2016-10-745133.","DOI":"10.1182\/blood-2016-10-745133"},{"issue":"3","key":"10.1016\/j.bmcl.2022.128603_b0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11899-018-0448-8","article-title":"Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes","volume":"13","author":"Dispenza","year":"2018","journal-title":"Curr Hematol Malig Rep."},{"issue":"8","key":"10.1016\/j.bmcl.2022.128603_b0090","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1007\/s00204-016-1918-1","article-title":"Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria","volume":"91","author":"Zhang","year":"2017","journal-title":"Arch Toxicol."},{"issue":"14","key":"10.1016\/j.bmcl.2022.128603_b0095","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.2174\/1389200219666180629112943","article-title":"Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Platelet-derived Growth Factor Receptor (PDGFR) Kinase Inhibitors","volume":"19","author":"Qian","year":"2018","journal-title":"Curr Drug Metab."},{"key":"10.1016\/j.bmcl.2022.128603_b0100","doi-asserted-by":"crossref","unstructured":"Cools J, Quentmeier H, Huntly BJP, et al. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA\u2013positive chronic eosinophilic leukemia. Blood. 2004;103(7):2802-2805. 10.1182\/blood-2003-07-2479.","DOI":"10.1182\/blood-2003-07-2479"},{"key":"10.1016\/j.bmcl.2022.128603_b0105","doi-asserted-by":"crossref","unstructured":"Lierman E, Folens C, Stover EH, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFR\u03b1 and the imatinib-resistant FIP1L1-PDGFR\u03b1 T674I mutant. Blood. 2006;108(4):1374-1376. 10.1182\/blood-2006-02-004457.","DOI":"10.1182\/blood-2006-02-004457"},{"issue":"4","key":"10.1016\/j.bmcl.2022.128603_b0110","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.exphem.2013.12.007","article-title":"Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA","volume":"42","author":"Sadovnik","year":"2014","journal-title":"Exp Hematol."},{"key":"10.1016\/j.bmcl.2022.128603_b0115","doi-asserted-by":"crossref","unstructured":"Goel S, O\u2019Shaughnessy J, Tan AR, et al. Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2). J Clin Oncol. 2021;39(15_suppl):TPS1107-TPS1107. 10.1200\/JCO.2021.39.15_suppl.TPS1107.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1107"},{"issue":"2","key":"10.1016\/j.bmcl.2022.128603_b0120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat Rev Cancer."},{"issue":"12","key":"10.1016\/j.bmcl.2022.128603_b0125","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib","volume":"59","author":"Groenland","year":"2020","journal-title":"Clin Pharmacokinet."},{"issue":"15","key":"10.1016\/j.bmcl.2022.128603_b0130","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1021\/jm4006884","article-title":"A Novel Series of Highly Potent 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitors","volume":"56","author":"Guck\u00fd","year":"2013","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128603_b0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejmech.2012.06.036","article-title":"Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases","volume":"61","author":"Zatloukal","year":"2013","journal-title":"Eur J Med Chem."},{"issue":"4","key":"10.1016\/j.bmcl.2022.128603_b0140","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1021\/jm960666x","article-title":"Cytokinin-Derived Cyclin-Dependent Kinase Inhibitors: Synthesis and cdc2 Inhibitory Activity of Olomoucine and Related Compounds","volume":"40","author":"Havl\u00ed\u010dek","year":"1997","journal-title":"J Med Chem."},{"issue":"20","key":"10.1016\/j.bmcl.2022.128603_b0145","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.2174\/138161212800672804","article-title":"Cyclin-dependent kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres","volume":"18","author":"Jorda","year":"2012","journal-title":"Curr Pharm Des."},{"issue":"4","key":"10.1016\/j.bmcl.2022.128603_b0150","first-page":"1435","article-title":"Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator","volume":"15","author":"Hsieh","year":"2009","journal-title":"Undifferentiated Nasopharyngeal Cancer. Clin Cancer Res."},{"issue":"18","key":"10.1016\/j.bmcl.2022.128603_b0155","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.ejca.2010.08.001","article-title":"Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies","volume":"46","author":"Le Tourneau","year":"2010","journal-title":"Eur J Cancer."},{"issue":"23","key":"10.1016\/j.bmcl.2022.128603_b0160","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1016\/j.bmcl.2009.10.025","article-title":"Biaryl purine derivatives as potent antiproliferative agents: Inhibitors of cyclin dependent kinases","volume":"19","author":"Trova","year":"2009","journal-title":"Part I. Bioorg Med Chem Lett."},{"issue":"23","key":"10.1016\/j.bmcl.2022.128603_b0165","doi-asserted-by":"crossref","first-page":"6613","DOI":"10.1016\/j.bmcl.2009.10.011","article-title":"Heterobiaryl purine derivatives as potent antiproliferative agents: Inhibitors of cyclin dependent kinases","volume":"19","author":"Trova","year":"2009","journal-title":"Part II. Bioorg Med Chem Lett."},{"issue":"44","key":"10.1016\/j.bmcl.2022.128603_b0170","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1038\/onc.2008.191","article-title":"CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases","volume":"27","author":"Bettayeb","year":"2008","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.bmcl.2022.128603_b0175","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","article-title":"Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor","volume":"9","author":"Parry","year":"2010","journal-title":"Mol Cancer Ther."},{"issue":"5","key":"10.1016\/j.bmcl.2022.128603_b0180","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/ml100051d","article-title":"Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases","volume":"1","author":"Paruch","year":"2010","journal-title":"ACS Med Chem Lett."},{"issue":"12","key":"10.1016\/j.bmcl.2022.128603_b0185","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/leu.2012.144","article-title":"The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells","volume":"26","author":"Johnson","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bmcl.2022.128603_b0190","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00280-012-1967-y","article-title":"Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies","volume":"70","author":"Zhang","year":"2012","journal-title":"Cancer Chemother Pharmacol."},{"issue":"7","key":"10.1016\/j.bmcl.2022.128603_b0195","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/pbc.24073","article-title":"Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program","volume":"59","author":"Gorlick","year":"2012","journal-title":"Pediatr Blood Cancer."},{"issue":"9","key":"10.1016\/j.bmcl.2022.128603_b0200","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1021\/acs.jmedchem.7b01529","article-title":"Discovery of N 2 -(4-Amino-cyclohexyl)-9-cyclopentyl- N 6 -(4-morpholin-4-ylmethyl-phenyl)- 9H -purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations","volume":"61","author":"Guck\u00fd","year":"2018","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128603_b0205","doi-asserted-by":"crossref","first-page":"111663","DOI":"10.1016\/j.ejmech.2019.111663","article-title":"Activity of 2,6,9-trisubstituted purines as potent PDGFR\u03b1 kinase inhibitors with antileukaemic activity","volume":"182","author":"\u0158ezn\u00ed\u010dkov\u00e1","year":"2019","journal-title":"Eur J Med Chem."},{"issue":"2","key":"10.1016\/j.bmcl.2022.128603_b0210","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1021\/jo961580e","article-title":"Building Units for N-Backbone Cyclic Peptides. 3. Synthesis of Protected N \u03b1 -(\u03c9-Aminoalkyl)amino Acids and N \u03b1 -(\u03c9-Carboxyalkyl)amino Acids","volume":"62","author":"Muller","year":"1997","journal-title":"J Org Chem."},{"issue":"14","key":"10.1016\/j.bmcl.2022.128603_b0215","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/S0040-4039(01)00282-9","article-title":"An efficient and practical method for the synthesis of mono-N-protected \u03b1, \u03c9-diaminoalkanes","volume":"42","author":"Lee","year":"2001","journal-title":"Tetrahedron Lett."},{"issue":"17","key":"10.1016\/j.bmcl.2022.128603_b0220","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1021\/jo061114h","article-title":"Revisiting Nucleophilic Substitution Reactions: Microwave-Assisted Synthesis of Azides, Thiocyanates, and Sulfones in an Aqueous Medium","volume":"71","author":"Ju","year":"2006","journal-title":"J Org Chem."},{"issue":"4","key":"10.1016\/j.bmcl.2022.128603_b0225","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1021\/jm001043t","article-title":"Crystal Structure of Human Cyclin-Dependent Kinase 2 in Complex with the Adenine-Derived Inhibitor H717","volume":"44","author":"Dreyer","year":"2001","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128603_b0230","doi-asserted-by":"crossref","first-page":"112322","DOI":"10.1016\/j.ejmech.2020.112322","article-title":"Design, synthesis and biological evaluation of novel histone deacetylase1\/2 (HDAC1\/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer","volume":"198","author":"Yun","year":"2020","journal-title":"Eur J Med Chem."},{"issue":"4","key":"10.1016\/j.bmcl.2022.128603_b0235","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1021\/ja01609a099","article-title":"A New Method of Forming Peptide Bonds","volume":"77","author":"Sheehan","year":"1955","journal-title":"J Am Chem Soc."},{"issue":"12","key":"10.1016\/j.bmcl.2022.128603_b0240","doi-asserted-by":"crossref","first-page":"o1951","DOI":"10.1107\/S1600536803025704","article-title":"N -Hydroxysuccinimide","volume":"59","author":"Jones","year":"2003","journal-title":"Acta Crystallogr Sect E Struct Reports Online."},{"key":"10.1016\/j.bmcl.2022.128603_b0245","doi-asserted-by":"crossref","unstructured":"Anderson GW, Zimmerman JE, Callahan FM. N-Hydroxysuccinimide Esters in Peptide Synthesis. J Am Chem Soc. 1963;85(19):3039-3039. 10.1021\/ja00902a047.","DOI":"10.1021\/ja00902a047"},{"issue":"7","key":"10.1016\/j.bmcl.2022.128603_b0250","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1021\/jm700964u","article-title":"Design and Synthesis of 4-Substituted Indolo[3,2- e ][1,2,3]triazolo[1,5- a ]pyrimidine Derivatives with Antitumor Activity","volume":"51","author":"Lauria","year":"2008","journal-title":"J Med Chem."},{"issue":"10","key":"10.1016\/j.bmcl.2022.128603_b0255","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1021\/ja00063a082","article-title":"1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive","volume":"115","author":"Carpino","year":"1993","journal-title":"J Am Chem Soc."},{"issue":"1","key":"10.1016\/j.bmcl.2022.128603_b0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568011033353605","article-title":"Chemical and Biological Profile of Dual Cdk1 and Cdk2 Inhibitors","volume":"3","author":"Ruetz","year":"2003","journal-title":"Curr Med Chem Agents."},{"key":"10.1016\/j.bmcl.2022.128603_b0265","unstructured":"Haesslein J-L. Derivatives of purine, their preparation process and pharmaceutical compositions containing them, US2005\/187228 A1."},{"issue":"18","key":"10.1016\/j.bmcl.2022.128603_b0270","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/S0960-894X(03)00648-6","article-title":"Bone-Targeted 2,6,9-Trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases","volume":"13","author":"Wang","year":"2003","journal-title":"Bioorg Med Chem Lett."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22000798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22000798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:43:43Z","timestamp":1760773423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22000798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":54,"alternative-id":["S0960894X22000798"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128603","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and biological activity evaluation of novel 2,6,9-trisubstituted purine conjugates as potential protein kinases inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128603"}}